Synergy Pharmaceuticals to Present at 2014 UBS Global Healthcare Conference

  Synergy Pharmaceuticals to Present at 2014 UBS Global Healthcare Conference

UBS 2014 Global Healthcare Conference

Business Wire

NEW YORK -- May 14, 2014

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and
Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at
the UBS Global Healthcare Conference on Monday, May 19, 2014 at 9:30am (ET) at
the Sheraton New York Times Square Hotel in New York City.

A live webcast of Synergy’s presentation will be accessible through the
Investors section of the company’s website at www.synergypharma.com. To access
the webcast, please log on to the Synergy website approximately 15 minutes
prior to the start time to ensure adequate time for any software downloads
that may be required. A replay of the webcast will be available on Synergy’s
website for 180 days following the conference.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals (NASDAQ: SGYP) is a biopharmaceutical company focused
on the development of novel therapies based on the natural human hormone,
uroguanylin, to treat gastrointestinal diseases and disorders. Uroguanylin is
a natural hormone produced by humans in the small intestine and plays a key
role in regulating the normal functioning of the digestive tract through its
activity on the guanylate cyclase-C (GC-C) receptor. The GC-C receptor is
known to be a primary source for stimulating a variety of beneficial
physiological responses. Synergy has created two unique analogs of uroguanylin
– plecanatide and SP-333 – designed to mimic the natural hormone’s activity on
the GC-C receptor and target a variety of gastrointestinal conditions.
Plecanatide is currently in two pivotal phase 3 clinical trials for chronic
idiopathic constipation and has successfully completed a phase 2b dose-ranging
study in patients with irritable bowel syndrome with constipation. SP-333 is
currently in phase 2 development for opioid-induced constipation and is also
being explored for ulcerative colitis. For more information, please visit
www.synergypharma.com.

Contact:

Company:
Synergy Pharmaceuticals Inc.
Gem Gokmen, 212-584-7610
ggokmen@synergypharma.com
 
Press spacebar to pause and continue. Press esc to stop.